Compare Repligen Corporation Common Stock (RGEN) vs Ross Stores, Inc. (ROST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Ross Stores, Inc. — how do they compare? Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B), while Ross Stores, Inc. trades at $232.6 (market cap $73.66B). The key difference: Ross Stores, Inc. is far larger — about 6.5× Repligen Corporation Common Stock's market cap, and Ross Stores, Inc. pays a 0.77% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Ross Stores, Inc. for 48 Days on average.
| RGEN | ROST | |
|---|---|---|
Market Cap | $11.31B | $73.66B |
Volume | 1,216,919 | 1,784,732 |
Sector | Health | Consumer Cyclical |
52-Week High | $194.57 | $255.23 |
52-Week Low | $102.87 | $155.21 |
Typical Hold Time | 0 Days | 48 Days |
Enterprise Value | $11.20B | $74.11B |
Dividend Yield | — | 0.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Ross Stores (ROST) trades at $225.68, down slightly by 0.07% on the day, with a bearish technical signal despite strong fundamental performance. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $2.66 exceeding the $1.95 forecast. Revenue growth continues with 2025 reaching $21.13B, while maintaining robust profitability with a 10.85% net income margin and exceptional 42.63% return on equity.
Wall Street maintains a bullish outlook with 64% buy ratings and a $274.14 consensus price target representing 21% upside potential. Key risks include competitive pressures in discount retail and potential margin compression from expansion costs. The stock's current technical weakness presents a potential entry point for investors confident in the company's store expansion strategy and value-focused merchandising approach.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →
